Baxter International (BAX)
(Delayed Data from NYSE)
$40.13 USD
-0.10 (-0.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $40.16 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
BAX 40.13 -0.10(-0.25%)
Will BAX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BAX
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
BAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Reasons to Hold Baxter International (BAX) in Your Portfolio
Other News for BAX
3 Dividend Stocks For 10%+ Annual Returns
ResMed Inc's Meteoric Rise: Unpacking the 12% Surge in Just 3 Months
Nuwellis Announces Pricing of $2.7 Million Public Offering
My Pink Slip Picks: 3 CEOs That Need to Be Fired
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO